As confirmed by the finding that there are other immune checkpoints, such as CTLA4 and CD47, the expression of which is HIF‐1 regulated,27 and the role of the vessel normalization effect of ITPP treatment and the reduction in tumour stem cells also previously seen upon ITPP treatment,30 this method provides a powerful new means for controlling the immunological balance in the tumour, whereas avoiding the side effects associated with systemically blocking molecules, such as PD1 on NK cells or CD8+ T cells65 and PD‐L1 on T regulators.27, 65. This evidence concerns the gene TPP1 and neoplasm.